(2025) analyzed three newer medications for sickle cell disease (SCD) – l-glutamine, crizanlizumab, and voxelotor – focusing on their ability to reduce complications like pain crises.
While these drugs represent important advances, the review highlights the need to better understand their real-world effectiveness compared to older treatments like hydroxyurea.
The study emphasizes that while these therapies show promise in managing symptoms, gaps remain in understanding long-term benefits and how they work for different patients.
This research helps doctors and patients weigh treatment options while underscoring the ongoing need for more comprehensive solutions beyond current medications.
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
More Info 
Add to Calendar